Tyrosine Kinase Inhibitors Modulating B Cell Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as autoimmune diseases, thromboembolic diseases, and cancer lack effective tyrosine kinase inhibitors that can modulate B cell function without permanent B cell removal and have broader disease-modifying activities beyond B cell depletion.
Innovation Solution
Development of compounds like those in Formula (IA), (I′), and (I) that inhibit tyrosine kinases, including BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK, which are used in pharmaceutical compositions to treat these diseases by administering them to patients in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If B cells are permanently removed to treat autoimmune diseases, then B cell function is inhibited, but B cell depletion cannot be reversed and lacks broader disease-modifying activities
Solution Approach 1:
The patent uses BTK as an intermediary target instead of directly removing B cells. By inhibiting BTK, the compound modulates B cell function through a reversible mechanism that affects B cell signaling pathways without causing permanent depletion, thereby achieving both reliable inhibition and reversible control with broader disease-modifying activities
Solution Approach 2:
The invention changes the parameter from permanent B cell removal to reversible BTK inhibition. This parameter change allows dynamic control of B cell function, enabling the treatment to be adjusted or reversed as needed while also affecting other disease pathways through BTK's role in multiple cellular processes
2Ease of operation
If small-molecule BTK inhibitors are used instead of biologics, then the inherent advantage of small-molecules is achieved, but the compounds must selectively inhibit BTK without affecting other kinases
Solution Approach 1:
The patent applies local quality by designing the small-molecule inhibitor to specifically target the BTK active site with unique structural features that match BTK's binding pocket. The compound contains specific substituents and molecular architecture that create localized interactions with BTK amino acid residues, ensuring selective inhibition while maintaining the ease of operation associated with small-molecule drugs
Data Source
AI summary
The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.